This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.v.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Martin Kirchberg - Innovator in Tetracycline Antibiotics
Introduction
Martin Kirchberg is a notable inventor based in Halle, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of tetracycline antibiotics. His innovative work focuses on controlled release mechanisms that enhance the efficacy of these important medications.
Latest Patents
Martin Kirchberg holds a patent for "Tetracycline complexes with sustained activity." This invention relates to the controlled release of tetracycline antibiotics. Specifically, it involves a complex comprising a tetracycline compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, along with a divalent metal carboxylate. The patent outlines a pharmaceutical preparation that includes this complex, methods for manufacturing it, and its application in treating bacterial infections. The invention aims to maintain antibiotic activity over a prolonged period, particularly for the therapy and prophylaxis of acute, chronic, or recurrent periodontal disease.
Career Highlights
Throughout his career, Martin Kirchberg has worked with esteemed organizations, including the Fraunhofer Society for the Advancement of Applied Research. His work in these institutions has allowed him to contribute to significant advancements in pharmaceutical research and development.
Collaborations
Martin has collaborated with notable colleagues such as Mirko Buchholz and Andreas Kiesow. These partnerships have fostered a collaborative environment that enhances innovation and research in the field of antibiotics.
Conclusion
Martin Kirchberg's contributions to the field of tetracycline antibiotics demonstrate his commitment to advancing medical science. His innovative patent for sustained-release tetracycline complexes is a testament to his expertise and dedication to improving therapeutic outcomes.